摘要
目的分析抗结核、抗肿瘤同期应用治疗肺结核合并肺癌的效果。方法回顾性分析2021年1月至2024年8月贵阳市公共卫生救治中心肿瘤二科收治的553例肺结核合并肺癌患者的相关资料,根据治疗方法不同将其分为同期组(n=258,同时进行抗结核、抗肿瘤治疗)和间歇组(n=295,先进行抗结核治疗,后进行抗肿瘤治疗)。比较两组的治疗效果。结果同期组的肿瘤治疗总缓解率高于间歇组,差异具有统计学意义(P<0.05)。两组的抗结核治疗总有效率比较,差异无统计学意义(P>0.05)。治疗2个周期后,两组的癌胚抗原(CEA)、鳞状细胞癌抗原(SCCA)、糖类抗原50(CA50)、血沉均降低,且同期组低于间歇组(P<0.05)。两组的各项不良反应发生率比较,差异无统计学意义(P>0.05)。结论抗结核、抗肿瘤同期应用治疗肺结核合并肺癌可取得较好的近期效果,抗结核治疗效果未受到影响,且未增加毒副反应。
Objective To analyze the effect of anti-tuberculosis and anti-tumor simultaneous application in the treatment of pulmonary tuberculosis complicated with lung cancer.Methods The relevant data of 553 patients with pulmonary tuberculosis complicated with lung cancer admitted in the No.2 oncology department,Guiyang Public Health Clinical Center from January 2021 to August 2024 were retrospectively analyzed.According to different treatment methods,the patients were divided into same period group(n=258,anti-tuberculosis and anti-tumor treatment were performed at the same time)and intermittent group(n=295,anti-tuberculosis treatment was performed first,and then anti-tumor treatment was performed).The therapeutic effects of the two groups were compared.Results The total remission rate of tumor treatment in the same period group was higher than that in the intermittent group,and the difference was statistically significant(P<0.05).There was no significant difference in the total effective rate of anti-tuberculosis treatment between the two groups(P>0.05).After 2 cycles of treatment,the carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCCA),carbohydrate antigen 50(CA50)and erythrocyte sedimentation rate in the two groups decreased,and those in the same period group were lower than those in the intermittent group(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Anti-tuberculosis and anti-tumor simultaneous application treatment of pulmonary tuberculosis complicated with lung cancer can achieve better short-term results,without affecting the efficacy of anti-tuberculosis treatment or increasing toxic side effects.
作者
吴维巍
杜茜
WU Weiwei;DU Qian(No.2 Oncology Department,Guiyang Public Health Clinical Center,Guiyang 550001;Drug Rehabilitation Medical Center,Guizhou Province Women's Compulsory Isolation Drug Rehabilitation Center,Guiyang 550000,China)
出处
《临床医学研究与实践》
2025年第23期66-69,共4页
Clinical Research and Practice
关键词
抗结核
抗肿瘤
肺结核
肺癌
anti-tuberculosis
anti-tumor
pulmonary tuberculosis
lung cancer
